
Daiichi Sankyo to Lead Open Innovation Research on Cell Therapy
The BioSpectrumAsia website reported that Daiichi Sankyo Company, Mitsubishi UFJ Capital Co., and Tokyo Institute of Technology have announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell therapy. The research is the 4th OiDE Fund investment,
Comments Off on Daiichi Sankyo to Lead Open Innovation Research on Cell Therapy • Read this story »